SS
MYGN icon

Steve Schonfeld’s Myriad Genetics MYGN Stock Holding History

Steve Schonfeld’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.8K Sell
12,046
-88,662
-88% -$402K ﹤0.01% 2343
2026
Q1 		$453K Buy
100,708
+5,673
+6% +$29.6K ﹤0.01% 1427
2025
Q4 		$584K Buy
95,035
+39,586
+71% +$287K ﹤0.01% 1335
2025
Q3 		$401K Buy
55,449
+21,834
+65% +$130K ﹤0.01% 1747
2025
Q2 		$178K Buy
33,615
+4,145
+14% +$24.5K ﹤0.01% 1802
2025
Q1 		$261K Sell
29,470
-3,450
-10% -$41.4K ﹤0.01% 1848
2024
Q4 		$451K Buy
32,920
+14,475
+78% +$267K ﹤0.01% 1450
2024
Q3 		$505K Sell
18,445
-14,424
-44% -$390K ﹤0.01% 1426
2024
Q2 		$804K Buy
+32,869
New +$721K 0.01% 1294
2019
Q3 		– Sell
-59,400
Closed -$1.65M – 1164
2019
Q2 		$1.65M Sell
59,400
-44,054
-43% -$1.24M 0.06% 331
2019
Q1 		$3.44M Buy
103,454
+83,354
+415% +$2.54M 0.12% 229
2018
Q4 		$584K Buy
+20,100
New +$723K 0.02% 619

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Steve Schonfeld's MYGN Position: Q2 2026 in Review

Steve Schonfeld reduced its Myriad Genetics (MYGN) stake by 88% in Q2 2026, selling an estimated $402K and leaving 12,046 shares worth $68.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2343.

Steve Schonfeld first reported a position in MYGN in Q4 2018 and has held it in 12 quarters since. The position peaked at $3.44M in Q1 2019. 195 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Steve Schonfeld held 12,046 shares of Myriad Genetics worth $68.8K as of Q2 2026.
  • Steve Schonfeld sold 88,662 Myriad Genetics shares in Q2 2026, an estimated $402K.
  • Myriad Genetics made up ﹤0.01% of Steve Schonfeld's portfolio in Q2 2026, its #2343 holding.
  • Steve Schonfeld first reported a position in Myriad Genetics in Q4 2018 and has held it in 12 quarters since.
  • Steve Schonfeld's Myriad Genetics position peaked at $3.44M in Q1 2019.
  • 195 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.